Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Adenine
/ analogs & derivatives
Alanine
Amides
Anti-HIV Agents
/ therapeutic use
Antiviral Agents
/ therapeutic use
Dideoxynucleosides
/ therapeutic use
Drug Combinations
Drug Resistance, Viral
Emtricitabine
/ therapeutic use
HIV Infections
/ drug therapy
HIV-1
/ drug effects
Heterocyclic Compounds, 3-Ring
Heterocyclic Compounds, 4 or More Rings
/ therapeutic use
Humans
Lamivudine
/ therapeutic use
Piperazines
Pyridones
Reverse Transcriptase Inhibitors
/ therapeutic use
Tenofovir
/ therapeutic use
bictegravir
clinical trial
resistance
treatment naive
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
03
12
2018
accepted:
17
02
2019
pubmed:
26
2
2019
medline:
31
3
2020
entrez:
27
2
2019
Statut:
epublish
Résumé
In clinical studies GS-US-380-1489 (study 1489) and GS-US-380-1490 (study 1490), bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF), dolutegravir-abacavir-lamivudine (DTG-ABC-3TC), and dolutegravir plus emtricitabine-tenofovir alafenamide (DTG+F-TAF) treatment achieved high rates of virologic suppression in HIV-1 treatment-naive participants through week 48. Preexisting primary drug resistance was present at levels of 1.3% integrase strand transfer inhibitor resistance (INSTI-R), 2.7% nucleoside reverse transcriptase inhibitor resistance (NRTI-R), 14.1% nonnucleoside reverse transcriptase inhibitor resistance (NNRTI-R), and 3.5% protease inhibitor resistance (PI-R) in the 1,274 participants from these studies. These mutations did not affect treatment outcomes. Resistance analyses in 13 virologic failures found no emergent resistance to study drugs.
Identifiants
pubmed: 30803969
pii: AAC.02533-18
doi: 10.1128/AAC.02533-18
pmc: PMC6496090
pii:
doi:
Substances chimiques
Amides
0
Anti-HIV Agents
0
Antiviral Agents
0
Dideoxynucleosides
0
Drug Combinations
0
Heterocyclic Compounds, 3-Ring
0
Heterocyclic Compounds, 4 or More Rings
0
Piperazines
0
Pyridones
0
Reverse Transcriptase Inhibitors
0
abacavir, lamivudine drug combination
0
emtricitabine tenofovir alafenamide
0
Lamivudine
2T8Q726O95
bictegravir
8GB79LOJ07
Tenofovir
99YXE507IL
tenofovir alafenamide
EL9943AG5J
Emtricitabine
G70B4ETF4S
Adenine
JAC85A2161
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
Lancet HIV. 2017 Dec;4(12):e536-e546
pubmed: 28729158
AIDS Res Hum Retroviruses. 2010 Dec;26(12):1323-6
pubmed: 20961278
PLoS One. 2009;4(3):e4724
pubmed: 19266092
J Antimicrob Chemother. 2015 Nov;70(11):3080-6
pubmed: 26311843
Lancet. 2017 Nov 4;390(10107):2063-2072
pubmed: 28867497
Lancet. 2014 Jun 28;383(9936):2222-31
pubmed: 24698485
Lancet. 2013 Aug 24;382(9893):700-8
pubmed: 23830355
Clin Infect Dis. 2018 May 17;66(11):1689-1697
pubmed: 29253097
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
pubmed: 12520007
PLoS One. 2009 Aug 19;4(8):e6687
pubmed: 19690614
Lancet HIV. 2017 Dec;4(12):e547-e554
pubmed: 29107562
AIDS. 2017 Jun 19;31(10):1425-1434
pubmed: 28375875
J Antimicrob Chemother. 2016 Feb;71(2):362-6
pubmed: 26546669
AIDS Rev. 2008 Apr-Jun;10(2):67-84
pubmed: 18615118
Clin Infect Dis. 2014 Feb;58(3):423-31
pubmed: 24145878
J Antimicrob Chemother. 2016 Jul;71(7):1948-53
pubmed: 27029845
Lancet HIV. 2018 Jul;5(7):e347-e356
pubmed: 29925490
AIDS. 2014 Nov 28;28(18):2751-62
pubmed: 25493601
N Engl J Med. 2013 Nov 7;369(19):1807-18
pubmed: 24195548
Lancet. 2017 Nov 4;390(10107):2073-2082
pubmed: 28867499
Retrovirology. 2018 Aug 17;15(1):56
pubmed: 30119633
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097
pubmed: 27645238
Lancet HIV. 2018 Jul;5(7):e357-e365
pubmed: 29925489
J Virol. 2008 Sep;82(18):9228-35
pubmed: 18596095
Lancet. 2013 Mar 2;381(9868):735-43
pubmed: 23306000